Biopharma companies need to see the employer market clearly in the short and long-term to be able to understand payers management methods for orphan drugs and the impact those decisions will have on their drugs
Optum Specialty Fusion™ was launched to streamline treatment decision-making for care providers, helping patients get on their therapies faster
Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies
Centene’s recent acquisition of PANTHERx will play a major role in the company’s specialty pharmacy growth
BioMatrix offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions
Payers are planning for an increasing number of gene therapies being approved by developing new coverage programs
Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]
Big Data in Cancer Care: Limitations of Drug Claims VBCC – March 2016, Vol 7, No 2 – Employers’ Perspective Catherine E. Cooke, PharmD, BCPS F. Randy Vogenberg, PhD, RPh Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence; Principal, Institute for Integrated Healthcare Greenville, SC As one part of an ongoing macrotheme regarding big […]